Intestinal activation of notch signaling induces rapid onset hepatic steatosis and insulin resistance

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Fowler, Joanna C ^a   Zecchini, Vincent R ^a,b   Jones, Philip H ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTRACELLULAR DOMAIN OF NOTCH1; MUTANT PROTEIN; NOTCH RECEPTOR; RIBOSOME PROTEIN; RIBOSOME PROTEIN L29; UNCLASSIFIED DRUG; RPL29 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE MUTATION; GOBLET CELL; INSULIN RESISTANCE; INTESTINE FLORA; LIPOGRANULOMA; LIVER LEVEL; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SMALL INTESTINE; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; FATTY LIVER; GENETIC TRANSCRIPTION; GENETICS; INTESTINE MUCOSA; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; MUS MUSCULUS;

ANIMALS; FATTY LIVER; INSULIN RESISTANCE; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 79959208664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020767     Document Type: Article

References (59)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, et al. (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: 480-486.
2. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873.
3. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, et al. (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437-443.
4. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, et al. (2009) The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58: 1538-1544.
5. Adams LA, Sanderson S, Lindor KD, Angulo P, (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42: 132-138.
6. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351.
7. Savage DB, Semple RK, (2010) Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 21: 329-336.
8. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027-1031.
9. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, et al. (2009) A core gut microbiome in obese and lean twins. Nature 457: 480-484.
10. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, et al. (2008) Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 87: 1219-1223.
11. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, et al. (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49: 1877-1887.
12. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
13. Fiuza UM, Arias AM, (2007) Cell and molecular biology of Notch. J Endocrinol 194: 459-474.
14. Bray SJ, (2006) Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7: 678-689.
15. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G, (1995) Jagged: a mammalian ligand that activates Notch1. Cell 80: 909-917.
16. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, et al. (1995) Signalling downstream of activated mammalian Notch. Nature 377: 355-358.
17. Furriols M, Bray S, (2001) A model Notch response element detects Suppressor of Hairless-dependent molecular switch. Curr Biol 11: 60-64.
18. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, et al. (2005) Notch signals control the fate of immature progenitor cells in the intestine. Nature 435: 964-968.
19. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, et al. (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963.
20. Zecchini V, Domaschenz R, Winton D, Jones P, (2005) Notch signaling regulates the differentiation of post-mitotic intestinal epithelial cells. Genes Dev 19: 1686-1691.
21. Stanger BZ, Datar R, Murtaugh LC, Melton DA, (2005) Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A 102: 12443-12448.
22. Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, et al. (2009) Notch signaling controls liver development by regulating biliary differentiation. Development 136: 1727-1739.
23. Sparks EE, Huppert KA, Brown MA, Washington MK, Huppert SS, (2010) Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice. Hepatology 51: 1391-1400.
24. Kodama Y, Hijikata M, Kageyama R, Shimotohno K, Chiba T, (2004) The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology 127: 1775-1786.
25. McCright B, Lozier J, Gridley T, (2002) A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129: 1075-1082.
26. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, et al. (2008) Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 48: 607-616.
27. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, et al. (2004) Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 126: 1236-1246.
28. Lee JH, Wada T, Febbraio M, He J, Matsubara T, et al. (2010) A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139: 653-663.
29. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, et al. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1: 4.
30. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
31. van der Vusse GJ, van Bilsen M, Glatz JF, Hasselbaink DM, Luiken JJ, (2002) Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem 239: 9-15.
32. Sundaram M, Yao Z, (2010) Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) 7: 35.
33. Reddy JK, Rao MS, (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290: G852-858.
34. Inoue Y, Inoue J, Lambert G, Yim SH, Gonzalez FJ, (2004) Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis. J Biol Chem 279: 44740-44748.
35. Erion DM, Ignatova ID, Yonemitsu S, Nagai Y, Chatterjee P, et al. (2009) Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab 10: 499-506.
36. Dufour JF, Clavien PA, (2009) Signaling pathways in liver diseases Heidelberg Springer-Verlag.
37. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, et al. (2005) Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 14: 3565-3577.
38. Degrace P, Moindrot B, Mohamed I, Gresti J, Du ZY, et al. (2006) Upregulation of liver VLDL receptor and FAT/CD36 expression in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid. J Lipid Res 47: 2647-2655.
39. Brolinson A, Fourcade S, Jakobsson A, Pujol A, Jacobsson A, (2008) Steroid hormones control circadian Elovl3 expression in mouse liver. Endocrinology 149: 3158-3166.
40. Devgan V, Mammucari C, Millar SE, Brisken C, Dotto GP, (2005) p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev 19: 1485-1495.
41. Lemke U, Krones-Herzig A, Berriel Diaz M, Narvekar P, Ziegler A, et al. (2008) The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 8: 212-223.
42. Fischer A, Gessler M, (2007) Delta-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35: 4583-4596.
43. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
44. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, et al. (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102: 11070-11075.
45. Ley RE, Turnbaugh PJ, Klein S, Gordon JI, (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022-1023.
46. Stappenbeck TS, Wong MH, Saam JR, Mysorekar IU, Gordon JI, (1998) Notes from some crypt watchers: regulation of renewal in the mouse intestinal epithelium. Curr Opin Cell Biol 10: 702-709.
47. Meyer-Hoffert U, Hornef M, Henriques-Normark B, Normark S, Andersson M, et al. (2008) Identification of heparin/heparan sulfate interacting protein as a major broad-spectrum antimicrobial protein in lung and small intestine. FASEB J 22: 2427-2434.
48. Stoelting M, Geyer M, Reuter S, Reichelt R, Bek MJ, et al. (2009) Alpha/beta hydrolase 1 is upregulated in D5 dopamine receptor knockout mice and reduces O2- production of NADPH oxidase. Biochem Biophys Res Commun 379: 81-85.
49. Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, et al. (2006) Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 47: 2280-2290.
50. Anstee QM, Goldin RD, (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16.
51. Loomes KM, Russo P, Ryan M, Nelson A, Underkoffler L, et al. (2007) Bile duct proliferation in liver-specific Jag1 conditional knockout mice: effects of gene dosage. Hepatology 45: 323-330.
52. Nelson WR, O'Hopp SJ, (1969) A semiquantitative screening test and quantitative assay for total fecal fat. Clin Chem 15: 1062-1071.
53. Furet JP, Firmesse O, Gourmelon M, Bridonneau C, Tap J, et al. (2009) Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol 68: 351-362.
54. Li Y, Piatigorsky J, (2009) Targeted deletion of Dicer disrupts lens morphogenesis, corneal epithelium stratification, and whole eye development. Dev Dyn 238: 2388-2400.
55. Heidenfelder BL, Reif DM, Harkema JR, Cohen Hubal EA, Hudgens EE, et al. (2009) Comparative microarray analysis and pulmonary changes in Brown Norway rats exposed to ovalbumin and concentrated air particulates. Toxicol Sci 108: 207-221.
56. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3 PMID: 16646809.
57. Wu JC, Merlino G, Fausto N, (1994) Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 91: 674-678.
58. Darlington GJ, Bernhard HP, Miller RA, Ruddle FH, (1980) Expression of liver phenotypes in cultured mouse hepatoma cells. J Natl Cancer Inst 64: 809-819.
59. Strobl LJ, Hofelmayr H, Stein C, Marschall G, Brielmeier M, et al. (1997) Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. Immunobiology 198: 299-306.